Literature DB >> 17405746

Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.

Alain Berrebi1, Edit Feldberg, Irena Spivak, Lev Shvidel.   

Abstract

We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17405746     DOI: 10.3324/haematol.10684

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  2 in total

1.  Cutaneous and systemic plasmacytosis on the face: Effective treatment of a case using thalidomide.

Authors:  Sheng Fang; Kui Shan; Ai-Jun Chen
Journal:  Oncol Lett       Date:  2016-01-25       Impact factor: 2.967

Review 2.  Profile of pomalidomide and its potential in the treatment of myelofibrosis.

Authors:  Krisstina L Gowin; Ruben A Mesa
Journal:  Ther Clin Risk Manag       Date:  2015-04-02       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.